FDA FLOATS LEGISLATIVE AGENDA ON CAPITOL HILL; AGENCY SEEKS REDEFINITION OF CLASS II AS "SAFETY AND PERFORMANCE" CATEGORY, DEEMPHASIZING SUBSTANTIAL EQUIVALENCE
This article was originally published in The Gray Sheet
Executive SummaryAn FDA "wish list" of device legislative concepts seeks to redefine Class II as a category focused on "safety and performance" rather than "substantial equivalence."
You may also be interested in...
The North American trade organization’s new website offers consumers a gateway into the world of fragrance. Providing a “deep dive” into 50 fragrance ingredients, as well as overviews of perfumery, key regulations, and industry safety practices and sustainability efforts, the site extends FCA’s work to engage and inform consumers at a time of growing interest in manufactured scents.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.